Sam S. Chang

Sam S. Chang's AcademicInfluence.com Rankings

Sam S. Chang

Philosophy

#7837

World Rank

#11103

Historical Rank

Logic

#4872

World Rank

#6204

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Sam S. Chang Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sam S. Chang's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. (2016) (915)
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. (2007) (815)
Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) (612)
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (474)
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial (2018) (399)
Analysis of early complications after radical cystectomy: results of a collaborative care pathway. (2002) (350)
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (297)
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. (2007) (285)
Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. (2004) (281)
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. (2013) (268)
Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. (2003) (268)
Overview of prostate-specific membrane antigen. (2004) (243)
Protocol for the examination of specimens from patients with carcinoma of the prostate gland. (2009) (235)
Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. (2010) (233)
Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. (2011) (215)
Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. (2015) (193)
Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines (2015) (186)
Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. (2014) (186)
Re: Smoking Cessation: A Report of the Surgeon General. (2020) (182)
Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. (2003) (181)
Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. (2007) (181)
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. (2013) (173)
Enhanced Recovery Pathways Versus Standard Care After Cystectomy: A Meta-analysis of the Effect on Perioperative Outcomes. (2016) (172)
Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. (2005) (165)
Contemporary open radical cystectomy: analysis of perioperative outcomes. (2008) (161)
Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. (2002) (152)
Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. (2010) (142)
Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. (2005) (137)
Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. (2003) (134)
Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. (2004) (131)
Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. (2011) (130)
Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. (2014) (123)
Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. (2015) (121)
Kidney cancer, version 3.2015. (2015) (119)
Association of procedure volume with radical cystectomy outcomes in a nationwide database. (2007) (119)
Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. (2004) (118)
Tumour volume is an independent predictor of prostate‐specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer (2006) (114)
Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. (2003) (113)
Impact of surgeon and hospital volume on outcomes of radical prostatectomy. (2010) (109)
Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. (2002) (101)
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. (2012) (100)
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. (2011) (100)
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline Part I. (2021) (99)
Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. (2002) (97)
Renal cell cancer histological subtype distribution differs by race and sex (2016) (94)
Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. (2007) (94)
Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. (2002) (94)
Complications of contemporary radical nephrectomy: comparison of open vs. laparoscopic approach. (2004) (94)
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? (2013) (94)
Effects of obesity and height on prostate‐specific antigen (PSA) and percentage of free PSA levels among African‐American and Caucasian men (2006) (91)
Penile cancer: clinical presentation, diagnosis, and staging. (2010) (91)
Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. (2004) (90)
The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. (2013) (89)
Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology (2015) (88)
Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation (2012) (85)
Recent Changes in Prostate Cancer Screening Practices and Epidemiology (2017) (82)
Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. (2011) (82)
Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. (2007) (76)
National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. (2012) (75)
Kidney cancer, version 2.2014. (2014) (73)
Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. (2004) (72)
Testicular Cancer, Version 2.2015. (2015) (69)
Benefit of radical cystectomy in the elderly patient with significant co-morbidities. (2004) (67)
Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. (2011) (66)
Volume outcomes of cystectomy--is it the surgeon or the setting? (2012) (65)
Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. (2012) (64)
Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. (2008) (64)
Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy (2014) (62)
Prostate-specific Membrane Antigen (PSMA)-specific Monoclonal Antibodies in the Treatment of Prostate and Other Cancers (2004) (61)
Smaller prostate size predicts high grade prostate cancer at final pathology. (2010) (59)
Voiding function in women with orthotopic neobladder urinary diversion. (2012) (59)
Increasing use of observation among men at low risk for prostate cancer mortality. (2015) (57)
Partial nephrectomy safely preserves renal function in patients with a solitary kidney. (2003) (57)
Increased body mass index predicts increased blood loss during radical cystectomy. (2004) (56)
Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. (2015) (56)
Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. (2014) (55)
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. (2011) (55)
Pathological findings of gynecologic organs obtained at female radical cystectomy. (2002) (52)
Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. (2010) (52)
ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma (2012) (51)
Urethral recurrence in patients following orthotopic urinary diversion. (2004) (50)
The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy (2016) (49)
Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. (2002) (49)
Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. (2009) (48)
Kidney Cancer (2016) (48)
Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. (2014) (48)
Patterns of initial transitional cell recurrence in patients after cystectomy. (2006) (47)
Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma (2015) (47)
Urinary diversion trends at a high volume, single American tertiary care center. (2009) (47)
Comparison of transfusion requirements between open and robotic‐assisted laparoscopic radical prostatectomy (2010) (46)
Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: implications for cancer detection and biopsy strategy. (2006) (46)
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. (2021) (46)
Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. (2003) (46)
Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial (2019) (45)
The clinical role of prostate-specific membrane antigen (PSMA). (2002) (45)
Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. (2012) (44)
Impact of positive surgical margins after radical prostatectomy. (2006) (43)
Racial variation in the quality of surgical care for bladder cancer (2014) (43)
Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. (2002) (42)
Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy (2008) (40)
Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. (2009) (40)
Sperm banking: use and outcomes in patients treated for testicular cancer (2007) (40)
Short term complications from transurethral resection of bladder tumor. (2016) (37)
Management of carcinoma in situ of the bladder: best practice and recent developments (2015) (37)
Re: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. (2018) (37)
Prostate cancer serum biomarker discovery through proteomic analysis of alpha‐2 macroglobulin protein complexes (2008) (37)
A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. (2016) (37)
Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. (2015) (36)
A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. (2008) (35)
Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up. (2020) (35)
Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder (2014) (35)
Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device. (2003) (35)
Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway (2005) (35)
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. (2009) (34)
Bladder cancer, version 3.2020 (2020) (34)
The role of systemic cytotoxic therapy for prostate cancer (2009) (34)
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. (2017) (34)
Radical cystectomy for bladder cancer: the case for early intervention. (2005) (33)
Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. (2004) (32)
The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. (2002) (32)
Triaging Office-Based UrologY Procedures During the COVID-19 Pandemic (2020) (32)
Racial variation in the quality of surgical care for prostate cancer. (2012) (31)
Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma (2005) (31)
Primary endoscopic management versus open revision of ureteroenteric anastomotic strictures after urinary diversion--single institution contemporary series. (2009) (30)
Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? (2008) (30)
Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively (2012) (29)
Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. (2014) (29)
An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. (2014) (29)
Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues (2000) (27)
Testicular cancer. (2012) (27)
Increasing Utilization of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in the United States (2014) (27)
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer (2018) (26)
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. (2020) (25)
Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes (2009) (25)
Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation (2004) (25)
Treatment options for hormone-refractory prostate cancer. (2007) (25)
Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing (2017) (24)
Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. (2013) (24)
Non-muscle-invasive bladder cancer: the role of radical cystectomy. (2005) (23)
Dilemmas in the treatment of urothelial cancers of the prostate. (2009) (23)
Current controversies in the treatment of high-risk prostate cancer (2008) (23)
Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. (2011) (23)
Monoclonal antibodies and prostate-specific membrane antigen. (2004) (23)
Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. (2014) (22)
Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. (2014) (21)
Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology (2009) (21)
Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer (2017) (21)
Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. (2016) (21)
The evidence‐based pathway for peri‐operative management of open and robotically assisted laparoscopic radical prostatectomy (2007) (21)
Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base (2009) (20)
Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. (2012) (20)
Locally advanced prostate cancer: the role of surgical management (2009) (20)
Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. (2016) (20)
Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. (2002) (19)
Prognostic factors in T3b renal cell carcinoma (2009) (19)
Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. (2008) (19)
Association between Preoperative Albumin Levels and Length of Stay after Radical Cystectomy (2017) (19)
Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients. (2021) (19)
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. (2018) (19)
Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: A tale of two methods (2010) (19)
Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How To Manage Them. (2020) (18)
Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48 000 patients (2009) (18)
Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma. (2017) (18)
Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer (2008) (18)
Non-muscle invasive bladder cancer. (2013) (17)
Routine postoperative intensive care monitoring is not necessary after radical cystectomy. (2002) (17)
Morbidity and efficacy of genitofemoral nerve grafts with radical retropubic prostatectomy. (2005) (17)
Therapeutic Ultrasound and Prostate Cancer (2017) (16)
Lack of P16ink4a over expression in penile squamous cell carcinoma is associated with recurrence after lymph node dissection. (2015) (16)
Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. (2010) (16)
TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. (2017) (16)
Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection. (2002) (16)
Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. (2014) (15)
Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia (2007) (14)
Multiple physician recommendations for prostate cancer treatment: a Pandora's box for patients? (2010) (14)
Assessing urinary diversion experience in urologic residency programs-are we adequately training the next generation? (2006) (14)
Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. (2002) (14)
Positive influence of robotically assisted laparoscopic prostatectomy on the collaborative‐care pathway for open radical prostatectomy (2006) (14)
Utilizing the Tumor‐Node‐Metastasis Staging for Prostate Cancer: The Sixth Edition, 2002 (2008) (14)
Assessing retroperitoneal lymphadenectomy experience in United States urological residency programs. (2007) (13)
Guideline-based management of non-muscle invasive bladder cancer (2015) (13)
Toxicity following high‐dose salvage radiotherapy after radical prostatectomy (2007) (13)
Treatment of clinical stage I germ cell tumors. (2002) (13)
Short- and long-term complications of therapy for testicular cancer. (2007) (12)
Neovesical‐urethral anastomotic stricture after orthotopic urinary diversion: presentation and management (2007) (12)
Current chemotherapeutic approaches for androgen-independent prostate cancer. (2006) (11)
Causes of increased length of stay following radical cystectomy. (2002) (11)
Margin control in open radical prostatectomy: what are the real outcomes? (2010) (11)
Conduit Urinary Diversion. (2018) (10)
Effects of tumor size and location on survival in upper tract urothelial carcinoma after nephroureterectomy (2018) (10)
Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer. (2003) (10)
Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model. (2020) (9)
Open renal biopsy: comorbidities and complications in a contemporary series (2009) (9)
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. (2019) (9)
Re: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. (2015) (9)
8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer (2020) (8)
Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. (2016) (8)
Improvements in Safety and Recovery Following Cystectomy: Reassessing the Role of Pre-Operative Bowel Preparation and Interventions to Speed Return of Post-Operative Bowel Function (2013) (8)
Inflammatory myofibroblastic tumor of the urinary bladder in a 27‐year‐old woman with systemic lupus erythematosus (2008) (7)
Role and Indications of Organ-Sparing "Radical" Cystectomy: The Importance of Careful Patient Selection and Counseling. (2018) (7)
Optimizing outcomes for octogenarians with invasive bladder cancer: One size does not fit all. (2013) (7)
Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma (2016) (7)
300: Prospective Assessment of Health Related Quality of Life (HRQOL) Urinary Diversion Following Radical Cystectomy and Urinary Diverision: Comparison of Orthotopic Neobladder Versus Ileal Conduit Patients (2004) (7)
High-Risk Non-Muscle Invasive Bladder Cancer: Selecting the Appropriate Patient for Timely Cystectomy. (2020) (7)
A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT (2019) (6)
Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. (2018) (6)
Feasibility study for image guided kidney surgery: assessment of required intraoperative surface for accurate image to physical space registrations (2006) (6)
An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival (2017) (6)
Management of High-grade T1 Urothelial Carcinoma (2018) (6)
Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: Comparison of short-term biochemical recurrencefree survival (2010) (5)
Lymphoma presenting as a solitary renal hilar mass. (2002) (5)
Re: Long-Term Outcome of Patients with Frequently Recurrent Non-Muscle-Invasive Bladder Carcinoma Treated with One Perioperative plus Four Weekly Instillations of Mitomycin C followed by Monthly bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomise (2017) (5)
1870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY (2013) (5)
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial. (2016) (5)
Treating octogenarians with muscle-invasive bladder cancer: preoperative opportunities for increasing the benefits of surgical intervention. (2014) (5)
Re: Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. (2015) (5)
Cost considerations in the management of bladder cancer (2017) (5)
ANTIBODIES TO THE INTERNAL AND EXTERNAL DOMAINS OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) REACT WITH TUMOR-ASSOCIATED NEOVASCULATURE (1999) (5)
Primary renal carcinoid tumor managed with laparoscopic partial nephrectomy. (2006) (5)
The impact of hospital volume on short-term and long-term outcomes for patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. (2020) (4)
RADICAL NEPHRECTOMY SURGICAL OUTCOMES IN THE UNIVERSITY HEALTHSYSTEM CONSORTIUM DATABASE: THE IMPACT OF HOSPITAL CASE VOLUME, HOSPITAL SIZE AND GEOGRAPHIC LOCATION ON 40,000 PATIENTS (2008) (4)
12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. (2012) (4)
Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion. (2022) (4)
1605: Early and Delayed Return of Urinary Continence after Radical Prostatectomy: Results of a Prospective Comparative Trial of an Open Retropubic vs. Robotic Approach (2007) (4)
The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer (2014) (4)
Re: EAU Guidelines on Penile Cancer: 2014 Update. (2016) (4)
Performance-enhancing supplement use in patients with testicular cancer. (2005) (4)
Polycystic kidney disease (1989) (4)
Kidney cancer: The prognostic value of urinary collecting system invasion (2009) (4)
THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
MP13-03 IMPACT OF SYNCHRONOUS BLADDER CANCER ON RECURRENCE-FREE SURVIVAL AFTER SURGICAL TREATMENT FOR PRIMARY URETHRAL CANCER: RESULTS FROM THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMA (ICPUC) (2014) (4)
726: Squamous Cell Carcinoma of the Penis: A Contemporary Review of Lymph Node Disease (2005) (3)
Re: Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study. (2018) (3)
Re: Risks and Benefits of Adjuvant Radiotherapy after Inguinal Lymphadenectomy in Node-Positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. (2019) (3)
456: Sperm Banking: Use and Outcomes in Patients Treated for Testicular Cancer (2006) (3)
Short- and long-term issues regarding urethral management in male radical-cystectomy patients (2005) (3)
Re: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. (2019) (3)
Re: Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. (2020) (3)
Re: Gender-Specific Differences in Clinicopathologic Outcomes following Radical Cystectomy: An International Multi-Institutional Study of More than 8000 Patients. (2016) (3)
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (2022) (3)
Re: Intravesical rAd-IFNα/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. (2018) (3)
A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer. (2015) (3)
Urological SurveyUrological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of OncologyRe: Conditional Survival after Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time (2015) (3)
A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT. (2020) (3)
Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. (2018) (3)
1818 PERIOPERATIVE BLOOD TRANSFUSION INCREASES THE RISK OF OVERALL MORTALITY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2010) (3)
The influence of provider characteristics and market forces on response to financial incentives. (2017) (3)
Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure. (2006) (3)
Principles of Bladder Cancer Surgery (2014) (3)
MP32-20 RECOVERY OF ERECTILE FUNCTION AFTER RADICAL PROSTATECTOMY: IDENTIFICATION OF TRAJECTORY CLUSTER GROUPS (2014) (3)
Catching Those Who Fall Through the Cracks: Integrating a Follow-Up Process for Emergency Department Patients with Incidental Radiologic Findings. (2022) (3)
A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer. (2016) (3)
Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial. (2016) (2)
PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS. (2021) (2)
Re: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy after Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit f (2017) (2)
Biology of PSMA As a Diagnostic and Therapeutic Target (2004) (2)
Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer. (2015) (2)
Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 Patients (2017) (2)
698: Laparoscopic, Hand Assisted Laparoscopic and open Simple Nephrectomy for Technically Challenging Cases (2007) (2)
Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. (2017) (2)
Accuracy of the Extent of Bladder Cancer Nodal Metastases Found at Pelvic Lymphadenectomy at the Time of Cystectomy: Relation to Primary Tumor Stage (2010) (2)
Re: HER2 as a Target in Invasive Urothelial Carcinoma. (2016) (2)
1586 BLOOD LOSS ASSOCIATED WITH RADICAL CYSTECTOMY A PROSPECTIVE RANDOMIZED STUDY COMPARING IMPACT LIGASURE VERSUS STAPLING DEVICE (2012) (2)
Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma (2021) (2)
Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy. (2019) (2)
Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. (2015) (2)
Management of Bladder Cancer (2015) (2)
Re: Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. (2020) (2)
The prevention of extraction site incisional hernia after robotic-assisted radical prostatectomy (2021) (2)
Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. (2018) (2)
EFFECT OF PRE-OPERATIVE NUTRITIONAL DEFICIENCY ON MORTALITY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER (2011) (2)
Re: Conditional Survival after Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. (2015) (2)
943 PROGNOSTIC FACTORS AND OUTCOMES AFTER DEFINITIVE TREATMENT FOR PRIMARY URETHRAL CANCER: RESULTS FROM THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMA (2013) (2)
Re: Impact of Suboptimal Neoadjuvant Chemotherapy on Peri-Operative Outcomes and Survival after Robot-Assisted Radical Cystectomy: A Multicentre Multinational Study. (2018) (2)
Complications of Transrectal Ultrasound-Guided Prostate Biopsy (2013) (2)
The urinary tract (2012) (2)
The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. (2018) (2)
Fifth Joint Meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association (2010) (2)
Re: A Floating Hydrogel System Capable of Generating CO2 Bubbles to Diminish Urinary Obstruction after Intravesical Instillation. (2016) (2)
Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. (2017) (2)
Re: EMT- and Stroma-Related Gene Expression and Resistance to PD-1 Blockade in Urothelial Cancer. (2019) (2)
Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer. (2019) (2)
Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer. (2017) (2)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (2)
Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. (2019) (2)
Re: Bacillus Calmette-Guérin (BCG) Therapy Lowers the Incidence of Alzheimer's Disease in Bladder Cancer Patients. (2020) (2)
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION POST-NEOADJUVANT ANDROGEN DEPRIVATION THERAPY: COMPARISON OF 7311 AND HYBRITECH PM2J004.5 IN PARAFFIN EMBEDDED PROSTATE TISSUE (1999) (1)
IDENTIFICATION OF DISTINCT OUTCOMES CLUSTERS FOR URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY (2009) (1)
Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model. (2019) (1)
Re: DaPeCa-1: Diagnostic Accuracy of Sentinel Lymph Node Biopsy in 222 Patients with Penile Cancer at Four Tertiary Referral Centres-A National Study from Denmark. (2017) (1)
ANALYSIS OF EARLY AND LATE HOSPITAL READMISSIONS FOLLOWING RADICAL CYSTECTOMY (2009) (1)
Predictors of recurrence in patients with high-risk pathology after prostatectomy (2015) (1)
PD11-10 A 10-ITEM CHECKLIST CHECKLIST IMPROVES REPORTING OF CRITICAL PROCEDURAL ELEMENTS DURING TRANSURETHRAL RESECTION OF BLADDER TUMOR (2016) (1)
Re: Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors. (2015) (1)
Re: Utility and Significance of Ureteric Frozen Section Analysis during Radical Cystectomy. (2017) (1)
Re: Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery after Surgery Protocol. (2018) (1)
Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. (2017) (1)
Laparoscopic radical nephrectomy: When minimally invasive surgery may be too invasive (2003) (1)
Re: Treatment for Metastatic Penile Cancer after First-Line Chemotherapy Failure: Analysis of Response and Survival Outcomes. (2016) (1)
Re: Effectiveness of Adjuvant Chemotherapy after Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-Invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. (2019) (1)
The adverse consequences of delaying radical cystectomy (2006) (1)
Re: Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004-2013). (2019) (1)
Re: Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer. (2018) (1)
Re: Intravesical rAd-IFNα/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study (2018) (1)
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer (2022) (1)
Re: A Systematic Review and Meta-Analysis of Clinicopathologic Factors Linked to Intravesical Recurrence after Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. (2016) (1)
Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. (2019) (1)
Chapter 19 – Prognosis and Management of Invasive Transitional Cell Carcinoma (2005) (1)
Re: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer. (2017) (1)
Re: The Effect of Intravesical Chemotherapy in the Prevention of Intravesical Recurrence after Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Meta-Analysis. (2016) (1)
Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial. (2019) (1)
Re: Health-Related Quality of Life after Radical Cystectomy and Neobladder Reconstruction in Women: Impact of Voiding and Continence Status (2015) (1)
Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer. (2019) (1)
Re: Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer (2018) (1)
Re: Human Papillomavirus (HPV) Genotype- and Age-Specific Analyses of External Genital Lesions among Men in the HPV Infection in Men (HIM) Study. (2015) (1)
Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter? (2020) (1)
Treating asymptomatic patients with hormone‐refractory prostate cancer: hormonal manipulations for the urologist (2008) (1)
1465: Incidence and Significance of Hgpin on Prostate Biopsy: Results of a Large, Community-Based Pathology Referral Center (2005) (1)
Re: Disseminated Mycobacterium bovis Infection Post-Kidney Transplant following Remote Intravesical BCG Therapy for Bladder Cancer. (2019) (1)
NCCN Kidney Cancer Clinical Practice Guidelines in Oncology (2011) (1)
Advancing prostate cancer: treatment options for the urologist. (2006) (1)
527 CHANGING UTILIZATION OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPIES FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER PUBLICATION OF LANDMARK MANUSCRIPTS (2012) (1)
Detection of Extravesical Disease: A Lack of Bladder Cancer Markers (2009) (1)
MP18-15 EFFICACY OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) AS A PRIMARY MONOTHERAPY FOR LOW RISK LOCALIZED PROSTATE CANCER: OUTCOMES FROM THE ENLIGHT TRIAL (2011) (1)
178: Examining Contemporary Urinary Diversion: A Review of Changing Practice Patterns Diversion Selectivity (2007) (1)
Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions. (2020) (1)
Association between PSA and leptin, adiponectin, HbA1c, or C-peptide among African-American and Caucasian men (2007) (1)
Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody. (2013) (1)
Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy. (2022) (1)
Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience. (2016) (1)
Pharmacological treatments for BCG-refractory cancer of the urinary bladder (2008) (1)
1122: Assessing Intraoperative Factors that Prevent Orthotopic Urinary Diversion in Patients Undergoing Radical Cystectomy (2005) (1)
Re: Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival. (2016) (1)
Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. (2018) (1)
Re: The Association of ABO Blood Type with Disease Recurrence and Mortality among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. (2016) (1)
Lap pak for abdominal retraction. (2012) (1)
Re: Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. (2015) (1)
Re: Association of Germline Variants in the APOBEC3 Region with Cancer Risk and Enrichment with APOBEC-Signature Mutations in Tumors. (2018) (1)
Predicting the Probability of 90-day Survival in Elderly Bladder Cancer Patients Treated with Radical Cystectomy (2019) (1)
Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer (2016) (1)
IMMEDIATE SURGICAL OUTCOMES FOR RADICAL PROSTATECTOMY IN THE UNIVERSITY HEALTHSYSTEM CONSORTIUM DATABASE: THE IMPACT OF HOSPITAL CASE VOLUME, HOSPITAL SIZE, AND GEOGRAPHIC REGION ON 48,000 PATIENTS (2008) (1)
Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma. (2015) (1)
Re: Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-Muscle-Invasive Bladder Cancer. (2020) (1)
Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer. (2017) (1)
WAITING TIME FROM DIAGNOSIS TO NEPHRECTOMY FOR RENAL CELL CARCINOMA: DOES IT AFFECT SURVIVAL? (2008) (1)
939 USE OF ROBOTIC ASSISTED RADICAL CYSTECTOMY VERSUS OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER IS ASSOCIATED WITH DECREASED BLOOD LOSS AND PERIOPERATIVE TRANSFUSION RATE (2011) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
SURVIVAL OUTCOMES IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA (2008) (0)
Re: Treatment Trends and Outcomes for Patients with Lymph Node-Positive Cancer of the Penis. (2020) (0)
Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer. (2020) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: Concurrent Chemotherapy is Associated with Improved Survival in Elderly Patients with Bladder Cancer Undergoing Radiotherapy (2018) (0)
Re: Association between Number of Endoscopic Resections and Utilization of bacillus Calmette-Guérin Therapy for Patients with High-Grade, Non-Muscle-Invasive Bladder Cancer. (2018) (0)
Re: Prognostic Risk Stratification Derived from Individual Patient Level Data for Men with Advanced Penile Squamous Cell Carcinoma Receiving First-Line Systemic Therapy. (2016) (0)
Re: Multicenter Evaluation of the Role of UroVysion FISH Assay in Surveillance of Patients with Bladder Cancer: Does FISH Positivity Anticipate Recurrence? (2017) (0)
MP31-15 IMPACT OF HEALTH LITERACY ON DISCHARGE DISPOSITION FOLLOWING RADICAL CYSTECTOMY (2016) (0)
Re: Clinical and Therapeutic Factors Associated with Adverse Pathological Outcomes in Clinically Node-Negative Patients Treated with Neoadjuvant Cisplatin-Based Chemotherapy and Radical Cystectomy. (2017) (0)
Re: Efficacy of Long-Acting Octreotide on Reducing Mucus Production in Patients with Ileal Neobladder (2018) (0)
Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. (2017) (0)
Re: Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. (2016) (0)
MP84-19 EXTENT OF LYMPH NODE DISSECTION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA IS ASSOCIATED WITH BETTER SURVIVAL (2015) (0)
Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer. (2018) (0)
Re: Randomized Trial of Narrow-Band versus White-Light Cystoscopy for Restaging (Second-Look) Transurethral Resection of Bladder Tumors. (2015) (0)
Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma. (2016) (0)
Re: Spillover Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions. (2020) (0)
Editorial Comment. (2020) (0)
Re: Intravesical Gemcitabine in Combination with Mitomycin C as Salvage Treatment in Recurrent Non-Muscle-Invasive Bladder Cancer (2017) (0)
MP82-13 IMPACT OF VARIANT HISTOLOGY ON SURVIVAL AND RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
Re: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base. (2018) (0)
305: A Prospective Randomized Trial of Early vs. Traditional Post-Operative Feeding After Radical Cystectomy and Urinary Diversion (2004) (0)
1816 EFFECTS OF PRE-OPERATIVE NUTRITIONAL DEFICIENCY ON 90-DAY MORTALITY AND OVERALL SURVIVAL IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2010) (0)
Re: Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-A Prospective Double-Blind Clinical Study. (2019) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guérin. (2018) (0)
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: . (2019) (0)
Re: The Prognostic Significance of the Early Postoperative Neutrophil-to-Lymphocyte Ratio in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. (2017) (0)
The 6th American Urological Association and the Japanese Urological Association International Affiliate Society Meeting (2011) (0)
1648: The Influence of Histopathologic Method on Prostatic Carcinoma Incidence and Gleason Grade in Cystoprostatectomy Specimens (2007) (0)
1444 ACCESS TO CARE INFLUENCES ADHERENCE TO GUIDELINES FOR MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER (2013) (0)
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
Re: Response Rate to Chemotherapy after Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. (2019) (0)
Re: Extended versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder in Patients Undergoing Radical Cystectomy. (2020) (0)
Abstract A113: Association between NSAIDs and PSA, prostate volume, and prostate cancer (2008) (0)
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
PD52-08 PRE-OPERATIVE NARCOTIC USE IS ASSOCIATED WITH INCREASING LENGTH OF STAY AND POST-OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY (2019) (0)
Optical attenuation as an effective biomarker for the early detection of bladder cancer (2022) (0)
Re: Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. (2015) (0)
Urothelial carcinoma of the bladder and upper tracts (2007) (0)
Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study. (2016) (0)
Re: Population-Based Assessment of Racial/Ethnic Differences in Utilization of Radical Cystectomy for Patients Diagnosed with Bladder Cancer. (2019) (0)
696: Positive Influence of Robotic Assisted Laparoscopic Prostatectomy on the Collaborative Care Pathway for Open Radical Prostatectomy (2005) (0)
Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma (2017) (0)
Re: Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. (2015) (0)
Re: Frequent PD-L1 Expression in Primary and Metastatic Penile Squamous Cell Carcinoma: Potential Opportunities for Immunotherapeutic Approaches. (2018) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. (2018) (0)
Re: Racial and Economic Disparities in the Treatment of Penile Squamous Cell Carcinoma: Results from the National Cancer Database. (2016) (0)
Re: Cost Considerations for Systemic Therapy for Patients with Advanced Genitourinary Malignancies. (2020) (0)
Re: Intraoperative Continuous Norepinephrine Infusion Combined with Restrictive Deferred Hydration Significantly Reduces the Need for Blood Transfusion in Patients Undergoing Open Radical Cystectomy: Results of a Prospective Randomised Trial. (2016) (0)
Re: Intermediate-Term Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Urothelial Carcinoma. (2015) (0)
Non-muscle Invasive Bladder Cancer: Identifying Patients to Consider Timely, Initial Cystectomy (2020) (0)
Re: The Health Effects of Electronic Cigarettes. (2017) (0)
73 RACIAL VARIATION IN THE UTILIZATION OF HIGH-VOLUME SURGEONS AND HOSPITALS FOR RADICAL PROSTATECTOMY (2011) (0)
Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: Implications for the Selection of Candidates at Adjuvant Radiation Therapy. (2019) (0)
Commentary on significance of positive surgical margins. (2008) (0)
1908 AN UPDATED MODEL AND NOMOGRAM FOR SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (2013) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: Intracorporeal Robot-Assisted Radical Cystectomy, together with an Enhanced Recovery Programme, Improves Postoperative Outcomes by Aggregating Marginal Gains. (2019) (0)
1493: Significance of ASAP and HGPIN on Prostate Biopsy: Implications for Cancer Detection and Biopsy Strategy (2005) (0)
Re: Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. (2016) (0)
Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guérin: Results from European Organisation for Research and Treatment of Cancer Geni (2018) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
1750 NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: TRENDS IN UTILIZATION AND IMPLICATIONS FOR PATHOLOGIC STAGING IN THE NATIONAL CANCER DATABASE (2013) (0)
Re: Neutrophil-to-Lymphocyte Ratio as a Bladder Cancer Biomarker: Assessing Prognostic and Predictive Value in SWOG 8710 (2017) (0)
1619 ACCESS TO CARE PREDICTS ADEQUATE PELVIC LYMPH NODE DISSECTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER (2013) (0)
PD6-05 CHANGE IN PREDICTED PROGNOSIS AFTER RADICAL PROSTATECTOMY DURING FOLLOW-UP IN AN ACTIVE SURVEILLANCE COHORT (2015) (0)
Re: Contemporary Cost-Effectiveness Analysis Comparing Sequential bacillus Calmette-Guerin and Electromotive Mitomycin versus bacillus Calmette-Guerin Alone for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. (2015) (0)
1320: Patterns of Initial Transitional Cell Carcinoma Recurrence in Patients after Cystectomy (2005) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: Sustained-Release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. (2019) (0)
452: Obesity is Positively Correlated with PSA Recurrence and Time to PSA Recurrence in Patients Undergoing Radical Prostatectomy (2004) (0)
Re: Lessons from 151 Ureteral Reimplantations for Postcystectomy Ureteroenteric Strictures: . (2019) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2020) (0)
1251: Partial Nephrectomy: Alive and well in an Era of Minimally Invasive Surgery (2007) (0)
1497: Predictive Value of Proliferative Inflammatory Atrophy (PIA) for Prostate Cancer on Repeat Prostate Biopsy (2006) (0)
MP10-03 THE INFLUENCE OF ACCESS TO CARE ON ADHERENCE TO CLINICAL PRACTICE GUIDELINES FOR TESTIS CANCER (2014) (0)
Re: Impact of Molecular Subtypes in Muscle-Invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy (2018) (0)
Re: Cigarette Smoking is Associated with Adverse Pathological Response and Increased Disease Recurrence amongst Patients with Muscle-Invasive Bladder Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Cystectomy: A Single-Centre Experience. (2020) (0)
Re: Adjuvant Cisplatin-Based Combined Chemotherapy for Lymph Node (LN)-Positive Urothelial Carcinoma of the Bladder (UCB) after Radical Cystectomy (RC): A Retrospective International Study of >1500 Patients. (2016) (0)
1185 RECOVERY OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY: IDENTIFICATION OF TRAJECTORY CLUSTER GROUPS (2012) (0)
Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors. (2016) (0)
Re: Metastases in Normal-Sized Pelvic Lymph Nodes: Detection with Diffusion-Weighted MR Imaging. (2015) (0)
MP25-11 PHYSICIAN-LEVEL VARIATION IN THE USE OF OBSERVATION FOR LOCALIZED PROSTATE CANCER (2016) (0)
Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory. (2020) (0)
Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model (2022) (0)
Re: Racial Disparity and Survival Outcomes between African-American and Caucasian American Men with Penile Cancer. (2019) (0)
Renal surgery and its impact on chronic kidney disease: a continuing evolution in decision making. (2014) (0)
Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer. (2019) (0)
Re: The Cancer of the Bladder Risk Assessment (COBRA) Score: Estimating Mortality after Radical Cystectomy. (2018) (0)
PD41-04 ORAL NUTRITION INTERVENTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL (2018) (0)
1426 CONTEMPORARY MANAGEMENT OF SMALL RENAL MASSES: PARTIAL NEPHRECTOMY IS ASSOCIATED EXCLUSIVELY WITH TUMOR ANATOMIC COMPLEXITY (2012) (0)
Association between surgical volume and survival among patients with variant histologies of bladder cancer. (2021) (0)
Abstract 5067: An expressed retrogene of master embryonic stem cell factor OCT4 alters prostate cancer susceptibility (2014) (0)
Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients. (2020) (0)
RELATIONSHIP BETWEEN PROSTATE VOLUME AND PATHOLOGIC GRADE OF PROSTATE CANCER (2009) (0)
MP20-06 HOW A TRAINING PROGRAM INFLUENCES EARLY CAREER DECISION-MAKING AND JOB RETENTION IN UROLOGY (2021) (0)
PD18-03 THE IMPACT OF HOSPITAL VOLUME ON SHORT-TERM AND LONG-TERM OUTCOMES FOR PATIENTS UNDERGOING RADICAL NEPHROURETERECTOMY WITH UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
441 RACIAL VARIATION IN THE QUALITY OF CARE AMONG PATIENTS UNDERGOING CYSTECTOMY FOR BLADDER CANCER (2011) (0)
Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer. (2019) (0)
RELATIONSHIP OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY WITH MEDICAL COMORBIDITIES AND GLOBAL QUALITY OF LIFE PARAMETERS (2009) (0)
Re: Occult Metastases in Pelvic Lymphadenectomy Specimens from Patients with Urothelial Carcinoma of the Bladder. (2017) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
Assessing health related quality of life following radical cystectomy and urinary diversion Development and validation of thevanderbilt cystectomy index (2003) (0)
Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous bacillus Calmette-Guérin Therapy. (2019) (0)
966 ONCOLOGIC OUTCOMES FOLLOWING ROBOTIC-ASSISTED LAPAROSCOPIC VS. OPEN RADICAL PROSTATECTOMY FOR INTERMEDIATE AND HIGH-RISK PROSTATE CANCER (2013) (0)
324: The Outcomes in Patients with Pathologic Carcinoma-in-Situ-Only Disease at Radical Cystectomy (2004) (0)
LOWER SERUM ALBUMIN LEVELS ARE ASSOCIATED WITH LONGER LENGTHS OF STAY (LOS) FOLLOWING CYSTECTOMY: THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM: MP96‐17 (2017) (0)
Re: Advanced Small Cell Carcinoma of the Bladder: Clinical Characteristics, Treatment Patterns and Outcomes in 960 Patients and Comparison with Urothelial Carcinoma. (2017) (0)
Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study. (2016) (0)
Re: Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. (2015) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2021) (0)
Re: Adjuvant Sandwich Chemotherapy plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: A Randomized Phase 2 Trial. (2019) (0)
Re: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. (2020) (0)
Re: The Effect of Broader, Directed Antimicrobial Prophylaxis Including Fungal Coverage on Perioperative Infectious Complications after Radical Cystectomy. (2017) (0)
Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation. (2017) (0)
MP58-08 DO LOW RISK MEN IN AN ACTIVE SURVEILLANCE COHORT REQUIRE ANNUAL BIOPSIES? (2014) (0)
Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2021) (0)
Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases. (2020) (0)
Re: Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. (2017) (0)
Re: Predictors of Nodal Upstaging in Clinical Node Negative Patients with Penile Carcinoma: A National Cancer Database Analysis (2018) (0)
Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-Label, Ra (2019) (0)
Re: Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. (2019) (0)
Re: Intravesical bacillus Calmette-Guérin with Interferon-Alpha versus Intravesical bacillus Calmette-Guérin for Treating Non-Muscle-Invasive Bladder Cancer (2017) (0)
Testicle Carcinoma Surveillance Counterpoint: USA (2013) (0)
8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer (2020) (0)
PD02-03 UNDERLYING REASONS ASSOCIATED WITH HOSPITAL READMISSION FOLLOWING UROLOGIC SURGERY IN THE U.S. (2016) (0)
Re: Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer within a Large, Diverse Integrated Delivery System. (2020) (0)
Re: Urine Cytology is a Feasible Tool for Assessing Erythematous Bladder Lesions after Bacille Calmette-Guérin (BCG) Treatment. (2020) (0)
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
PD55-06 COMPARISON OF MRI/FUSION VERSUS TRUS CONFIRMATORY BIOPSY IN ACTIVE SURVEILLANCE PATIENTS (2019) (0)
574: Prospective Assessment of Health Related Quality of Life (HRQOL) at One Year Following Radical Cystectomy and Urinary Diversion (2007) (0)
Re: Outcome of Patients with Micropapillary Urothelial Carcinoma following Radical Cystectomy: ERBB2 (HER2) Amplification Identifies Patients with Poor Outcome (2015) (0)
Re: Clinical Significance of Preoperative C-Reactive Protein and Squamous Cell Carcinoma Antigen Levels in Patients with Penile Squamous Cell Carcinoma. (2018) (0)
IMPACT OF POSITIVE APICAL SURGICAL MARGINS (SM) ON THE LIKELIHOOD OF BIOCHEMICAL RECURRENCE (BCR) AFTER PROSTATECTOMY (2009) (0)
COMPARISON OF 3-YEAR CANCER CONTROL OUTCOMES IN ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY (RALP) VERSUS RADICAL RETROPUBIC PROSTATECTOMY (RRP) FOR PROSTATE CANCER (2009) (0)
Prostate Cancer: Clinical Case Scenarios. (2018) (0)
1413 PREDICTING THE PROBABILITY OF 90-DAY SURVIVAL IN ELDERLY BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY (2011) (0)
1900 WORTH A SECOND LOOK: RATES OF UPSTAGING AT THE TIME OF RADICAL CYSTECTOMY AFTER RESTAGING TURBT FOR PERSISTENT T1 UROTHELIAL CARCINOMA (2012) (0)
Re: Impact of Perioperative Chemotherapy on Survival in Patients with Advanced Primary Urethral Cancer: Results of the International Collaboration on Primary Urethral Carcinoma. (2015) (0)
Re: Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. (2020) (0)
977 ABO BLOOD TYPE IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA (2012) (0)
Re: Partial Bladder Boost Using Lipiodol Marking during Image-Guided Radiotherapy for Bladder Cancer. (2019) (0)
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. (2023) (0)
Re: Comparing Open Radical Cystectomy and Robot-Assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. (2015) (0)
Solifenacin at 3 Years: A Review of Efficacy and Safety (2008) (0)
Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer. (2019) (0)
UTILIZATION OF SYSTEMIC THERAPY IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA (2008) (0)
Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model. (2023) (0)
Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-Invasive Bladder Cancer: A Sign of Changing Tides. (2016) (0)
Re: Prognostic Significance of Lymphatic, Vascular and Perineural Invasion for Bladder Cancer Patients Treated by Radical Cystectomy. (2019) (0)
7of Extravesical Disease: A Lack of Bladder Cancer Markers (2010) (0)
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter (2022) (0)
Re: Pathologic Response in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Is Therapeutic Effect Owing to Chemotherapy or TURBT? (2019) (0)
Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. (2019) (0)
Re: Fluorescence-Guided Bladder Tumour Resection: Impact on Survival after Radical Cystectomy. (2015) (0)
MP13-08 GENDER INFLUENCE ON PRESENTATION, MANAGEMENT, AND OVERALL SURVIVAL IN PRIMARY URETHRAL CANCER (2014) (0)
Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. (2017) (0)
1226 PERIOPERATIVE COST COMPARISON OF ROBOTIC AND OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER (2012) (0)
Re: Evidenced-Based Clinical Practice Guideline for Upper Tract Urothelial Carcinoma (summary-Japanese Urological Association, 2014 edition). (2015) (0)
1763 TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF PATIENTS 50 YEARS OLD AND YOUNGER UNDERGOING DEFINITIVE TREATMENT FOR BLADDER UROTHELIAL CELL CARCINOMA (2012) (0)
1646 STATIN USE IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS UNDERGOING SURGERY FOR RENAL CELL CARCINOMA (2013) (0)
Re: Cost-Effectiveness of Neoadjuvant Chemotherapy before Radical Cystectomy for Muscle-Invasive Bladder Cancer. (2016) (0)
MP44-02 POST-OPERATIVE NARCOTIC PRESCRIBING PATTERNS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY (2019) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
Re: National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging. (2020) (0)
Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG. (2022) (0)
Kidney: renal cell carcinoma (2007) (0)
How a Large Academic Training Program Influences Early Career Decision-making and Employment Stability in Urology. (2022) (0)
Re: Potential Impact of 18F-FDG PET/CT on Patients Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. (2015) (0)
Re: SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor. (2017) (0)
Treatment principles for nonmuscle invasive bladder cancer (2008) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: Usefulness of pT1 Substaging in Papillary Urothelial Bladder Carcinoma. (2016) (0)
Re: Factors Influencing the Length of Stay after Radical Cystectomy: Implications for Cancer Care and Perioperative Management. (2016) (0)
Differentiation of Bladder Cancer from Inflammation with Polarization-Sensitive Optical Coherence Tomography (2022) (0)
Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
Impact of PSMA-targeted PET/CT in the clinical management of men with advanced prostate cancer. (2022) (0)
1030 ASSESSMENT OF THE 2002 AJCC NODAL STAGING OF BLADDER UROTHELIAL CARCINOMA (2010) (0)
Re: Nuclear CD24 Drives Tumor Growth and is Predictive of Poor Patient Prognosis (2018) (0)
PD12-06 INCREASED PAYMENT FOR OFFICE-BASED MANAGEMENT OF BLADDER CANCER: UNINTENDED CONSEQUENCES IN A FEE-FOR-SERVICE ENVIRONMENT (2015) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
Re: Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. (2016) (0)
Re: Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. (2019) (0)
Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence. (2019) (0)
Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations. (2017) (0)
488: Assessing Urinary Diversion Experience in Urologic Residency Training: Is it Adequate? (2005) (0)
528 PRE-OPERATIVE NUTRITIONAL STATUS IS AN IMPORTANT PREDICTOR OF SURVIVAL FOLLOWING SURGERY FOR RENAL CELL CARCINOMA (2011) (0)
PRIMARY ENDOSCOPIC MANAGEMENT VERSUS OPEN REVISION OF URETEROENTERIC ANASTOMOTIC STRICTURES FOLLOWING URINARY DIVERSION-SINGLE INSTITUTION CONTEMPORARY SERIES (2009) (0)
Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: . (2018) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients. (2017) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2020) (0)
New Approaches in the Treatment of Advanced Prostate Cancer (2006) (0)
Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. (2019) (0)
847: Is Length of Positive Surgical Margin an Independent Predictor of Biochemical Progression After Prostatectomy? Results of a Multivariate Analysis (2004) (0)
Re: Orthotopic Neobladder vs. Ileal Conduit Urinary Diversion: A Long-Term Quality-of-Life Comparison. (2017) (0)
Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. (2020) (0)
1878 SMALL CELL CARCINOMA OF THE BLADDER: CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS (2013) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles OF Oncology. (2021) (0)
Re: The Impact of Non-Urothelial Variant Histology on Oncological Outcomes following Radical Cystectomy. (2020) (0)
MP31-16 THE IMPACT OF HEALTH LITERACY ON SURGICAL OUTCOMES FOLLOWING RADICAL CYSTECTOMY (2016) (0)
Racial variation in the quality of care among patients undergoing cystectomy for bladder cancer (2011) (0)
Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG. (2023) (0)
MP42-10 TREATMENT AND ASSOCIATED SURVIVAL TRENDS FOR LOCALIZED SMALL CELL CARCINOMA OF THE BLADDER (2022) (0)
Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer. (2019) (0)
Laparoscopy and Robotics Biochemical Recurrenceefree Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer (2014) (0)
Urological Oncology: Bladder, Penis and Urethra Cancer, and Basic Principles of Oncology. (2021) (0)
QIM22-205: Implementation of a Comprehensive Pre-Habilitation Program for Patients Undergoing Radical Cystectomy (2022) (0)
A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T3a VERSUS T3b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES (2008) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
Treatment of muscle-invasive bladder cancer (2010) (0)
MP60-03 IMPACT OF POST-OPERATIVE COMPLICATIONS AND THE NUMBER OF ‘HOSPITAL-FREE DAYS’ FOLLOWING RADICAL CYSTECTOMY ON QUALITY OF LIFE AT ONE YEAR (2014) (0)
MP49-01 FOXA1 LOSS IS ASSOCIATED WITH POOR PROGNOSIS AND SEX-DEPENDENT PHENOTYPES FOLLOWING GENETIC INACTIVATION (2015) (0)
Re: Incidence of Bladder Cancer after Radiation for Prostate Cancer as a Function of Time and Radiation Modality (2018) (0)
1631 DISPARITIES IN THE UTILIZATION OF RADICAL CYSTECTOMY IN YOUNG PATIENTS WITHOUT COMORBIDITY: AN UNFORTUNATE TALE OF MISSED OPPORTUNITY (2013) (0)
Re: Variation in Performance of Candidate Surgical Quality Measures for Muscle-Invasive Bladder Cancer by Hospital Type. (2016) (0)
1803 A PROGNOSTIC MODEL FOR SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (2012) (0)
Office‐Based Cystoscopy: Continued Advances (2012) (0)
Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer. (2019) (0)
Re: Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to bacillus Calmette-Guérin. (2017) (0)
Re: Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated with Chemoradiation-Based Selective Bladder-Sparing Approach. (2015) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2020) (0)
1656 NATIONAL ASSESSMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PRACTICE PATTERNS: IMMEDIATE POST-OPERATIVE INSTILLATION OF CHEMOTHERAPY (IPOIC) (2011) (0)
Re: Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can we Actually Improve the Surgical Quality? (2017) (0)
Re: Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. (2017) (0)
Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. (2018) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
IMMUNOHISTOCHEMICAL COMPARISON OF FIVE ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) IN BENIGN TISSUES (1999) (0)
Re: Development and External Validation of a Prognostic Tool for Prediction of Cancer-Specific Mortality after Complete Loco-Regional Pathological Staging for Squamous Cell Carcinoma of the Penis. (2016) (0)
MP5-07 AN EMPIRICAL EVALUATION OF VARIATION IN INTENSITY OF SURVIVORSHIP CARE AND ITS EFFECT ON KIDNEY CANCER-SPECIFIC SURVIVAL (2015) (0)
Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer. (2020) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. (2020) (0)
Re: Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. (2015) (0)
1757 USE OF PELVIC LYMPHADENECTOMY IN RADICAL CYSTECTOMY FOR BLADDER CANCER: 10-YEAR EXPERIENCE AT A SINGLE INSTITUTION (2012) (0)
MP12-16 SURVEILLANCE IMAGING AFTER T1 RCC: AN OVER-UTILIZATION OR NECESSARY CARE? (2014) (0)
Follow-up imaging in the first two years after nephrectomy for T1 RCC: Over-use or necessary care? (2016) (0)
Re: A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 Inhibitor. (2019) (0)
Re: Practical Tips for Safe and Efficient Robotic Cystectomy. (2016) (0)
Re: Adjuvant Pelvic Radiation is Associated with Improved Survival and Decreased Disease Recurrence in Pelvic Node-Positive Penile Cancer after Lymph Node Dissection: . (2019) (0)
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
629 Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer (2016) (0)
OP3-11 INGUINAL LYMPHADENECTOMY IN PENILE CANCER: RESULTS FROM THE NATIONAL CANCER DATABASE (2014) (0)
PD31-09 INSTITUTIONAL MODIFICATION OF ANTIBIOTIC PROPHYLAXIS PROTOCOL REDUCES INFECTIOUS COMPLICATIONS FOLLOWING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY (2014) (0)
Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer. (2017) (0)
Office-based Cystoscopy (2018) (0)
1121: Assessing Gender Differences in Pathologic Characteristics and Disease-Specific Outcomes in Radical Cystectomy (2005) (0)
Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy. (2020) (0)
Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients. (2022) (0)
Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer. (2016) (0)
848: Tumor Volume is Positively Correlated with Pathologic Stage and PSA Recurrence in Patients Undergoing Radical Prostatectomy (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sam S. Chang?

Sam S. Chang is affiliated with the following schools:

Vanderbilt University

Sam S. Chang's Academic­Influence.com Rankings

Why Is Sam S. Chang Influential?

Sam S. Chang's Published Works

Published Works

What Schools Are Affiliated With Sam S. Chang?

Sam S. Chang's AcademicInfluence.com Rankings